The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885 on ClinicalTrials.gov · last registry update 2017-09-11

Finished September 2010, after enrolling 41 people. Primary outcome, as filed: Change in Weight. exenatide is approved in the US, but not for obesity and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Beth Israel Deaconess Medical Center
Sponsor type: Other
Enrollment: 41
Started: 2007-04
Primary completion: 2010-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Weight

Conditions studied

Obesity · Impaired Glucose Tolerance

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.